TX-001HR is the company's investigational bio-identical hormone therapy combination of estradiol and progesterone in a single, oral softgel for the treatment of moderate-to-severe vasomotor
symptoms due to menopause.
NYSE American: TXMD) has submitted the new drug application (NDA) for TX-001HR, its investigational bio-identical hormone therapy combination of estradiol and progesterone in a single, oral softgel for the treatment of moderate-to-severe vasomotor
symptoms due to menopause, to the US Food and Drug Administration, the company said.
Simon and his coinvestigators found that women taking the combination therapy saw reductions in the vasomotor
domain of MEN-QOL within 12 weeks of beginning the study.
In addition, Ogeda shareholders will become eligible to receive up to EUR 300m in further contingent payments based on progress in the development of fezolinetant, Ogeda's most advanced clinical program for the treatment of menopausal-related vasomotor
05, compared with placebo), as was vasomotor
Several herbal remedies, but not Chinese medicinal herbs, were associated with an overall decrease in the frequency of vasomotor
Patients with an anteroposterior deviation were not included in this study, nor were patients with vasomotor
rhinitis, allergic rhinitis, nasal polyposis, turbinate pathologies, or a systemic disease; also excluded were patients who were taking any medication and those who had undergone any previous nasal surgery.
Global Markets Direct's, 'Vasomotor
Symptoms of Menopause (Hot Flashes) - Pipeline Review, H1 2016', provides an overview of the Vasomotor
Symptoms of Menopause (Hot Flashes) pipeline landscape.
In spite of its popularity in the western countries as an alternative therapy for the menopausal vasomotor
problems, centrally active alpha-2 agonist clonidine is only marginally more effective than placebo, but considerably less efficient than estrogen .
However, the prevalence of vasomotor
symptoms does not have a similar distribution between menopausal stages and even in a given stage, in the population of menopausal women (Melby, Lock, & Kaufert, 2005).
USPRwire, Wed Dec 17 2014] Global Markets Direct's, 'Vasomotor
Symptoms of Menopause - Pipeline Review, H2 2014', provides an overview of the Vasomotor
Symptoms of Menopause's therapeutic pipeline.
5 mg in women with moderate-to-severe vasomotor